Dr. David Teng-Yi Huang leads the development of OBI Pharma’s next-generation Antibody-Drug Conjugate (ADC) technologies, including GlycOBI®, ThiOBI®, EndoSymeOBI®, HYPrOBI™ and GlycOBI DUO™. With deep expertise in carbohydrate chemistry and glycoengineering, he focuses on designing site-specific, homogeneous ADCs to improve stability, manufacturability, and applicability.
Under his leadership, OBI has advanced multiple clinical and preclinical ADC candidates. Dr. Huang is also a key contributor to OBI’s intellectual property portfolio and plays an active role in global business development.
He received his Ph.D. in Chemistry from National Tsing Hua University and completed postdoctoral training at Academia Sinica, where he specialized in glycoscience for biomedical applications.